Liquid Biopsy  – Ein neues diagnostisches Konzept in der Onkologie

Isabel Heidrich; Carmen M.T. Roeper; Charlotte Rautmann; Klaus Pantel; Daniel J. Smit

doi:10.1055/a-1928-0225

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2023; 148(10): 597-604
DOI: 10.1055/a-1928-0225

Dossier

Liquid Biopsy – Ein neues diagnostisches Konzept in der Onkologie

Liquid Biopsy - A new diagnostic concept in oncology

Isabel Heidrich‡

¹Klinik und Poliklinik für Dermatologie und Venerologie, Fleur Hiege-Centrum für Hautkrebsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

²Institut für Tumorbiologie, Fleur Hiege-Centrum für Hautkrebsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

³Mildred-Scheel-Nachwuchszentrum, Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

,

Carmen M.T. Roeper‡

¹Klinik und Poliklinik für Dermatologie und Venerologie, Fleur Hiege-Centrum für Hautkrebsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

,

Charlotte Rautmann

¹Klinik und Poliklinik für Dermatologie und Venerologie, Fleur Hiege-Centrum für Hautkrebsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

,

Klaus Pantel

²Institut für Tumorbiologie, Fleur Hiege-Centrum für Hautkrebsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

,

Daniel J. Smit

²Institut für Tumorbiologie, Fleur Hiege-Centrum für Hautkrebsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

› Author Affiliations

Abstract

Die Analyse von im Blut zirkulierenden Tumorzellen oder von in anderen Körperflüssigkeiten zirkulierenden Tumorzellprodukten gewann in den letzten Jahren stetig an Aufmerksamkeit. Sie wird unter dem Begriff Flüssigbiopsie (Liquid Biopsy, LB) zusammengefasst. In diesem Beitrag werden die wichtigsten LB-Analyten vorgestellt sowie die noch bestehenden Hürden und vielfältigen Bemühungen der Implementierung der LB in die klinische Routine diskutiert.

Abstract

The analysis of tumor cells circulating in the blood or of products of tumor cells circulating in other body fluids has gained increasing attention in recent years and is summarized under the term liquid biopsy (LB). LB includes the analysis of circulating tumor cells, cell-free circulating tumor-associated nucleic acids, extracellular vesicles, proteins, or other products that are released into the peripheral bloodstream by the primary or metastatic tumor. For a huge number of solid tumor entities, LB has already been successfully applied in preclinical and clinical studies for the detection, risk stratification, treatment monitoring and relapse detection. LB provides valuable real-time information on tumor cell development, therapeutic targets, and mechanisms of therapy resistance using a non-invasive peripheral blood test. In this article, the most important LB analytes and the current state of research are presented. In addition, the remaining obstacles and the diverse efforts to implement LB in clinical routine are critically discussed.

Schlüsselwörter

Liquid Biopsy - zirkulierende Tumor‐DNA - zirkulierende Tumorzellen - minimale Resterkrankung - Therapieüberwachung - zielgerichtete Therapien

Keywords

Liquid Biopsy - ctDNA - CTCs - MRD - therapeutic decision making - targeted therapy

Full Text

References

Literatur
1 Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell 2017; 31: 172-179
2 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249
3 Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010; 16: 398-406
4 Alix-Panabières C, Pantel K. Liquid biopsy: From discovery to clinical application. Cancer Discov 2021; 11: 858-873
5 Cheng YH, Chen YC, Lin E. et al. Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat Commun 2019; 10: 2163
6 Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease – latest advances and implications for cure. Nat Rev Clin Oncol 2019; 16: 409-424
7 Smit DJ, Pantel K, Jücker M. Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. Biochem Pharmacol 2021; 188: 114589
8 Thierry AR, El Messaoudi S, Gahan PB. et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev 2016; 35: 347-376
9 Yu W, Hurley J, Roberts D. et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol 2021; 32: 466-477
10 Liu J, Jennings SF, Tong W. et al. Next generation sequencing for profiling expression of miRNAs: technical progress and applications in drug development. J Biomed Sci Eng 2011; 4: 666-676
11 Hoshino A, Kim HS, Bojmar L. et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 2020; 182: 1044-1061.e1018
12 Ding Z, Wang N, Ji N. et al. Proteomics technologies for cancer liquid biopsies. Mol Cancer 2022; 21: 53
13 Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics 2019; 13: 34
14 Nicolazzo C, Barault L, Caponnetto S. et al. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer Lett 2021; 507: 89-96
15 Newman AM, Bratman SV, To J. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20: 548-554
16 Cohen JD, Li L, Wang Y. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science (New York, NY) 2018; 359: 926-930
17 Liu MC, Oxnard GR, Klein EA. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020; 31: 745-759
18 Cristiano S, Leal A, Phallen J. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 2019; 570: 385-389
19 Heidrich I, Ačkar L, Mossahebi Mohammadi P. et al. Liquid biopsies: Potential and challenges. Int J Cancer 2021; 148: 528-545
20 Bidard FC, Kiavue N, Ychou M. et al. Circulating tumor cells and circulating tumor DNA detection in potentially resectable metastatic colorectal cancer: a prospective ancillary study to the Unicancer Prodige-14 Trial. Cells 2019; 8: 516
21 Woodhouse R, Li M, Hughes J. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PloS one 2020; 15: e0237802
22 Razavi P, Dickler MN, Shah PD. et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer 2020; 1: 382-393
23 Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic – implementation issues and future challenges. Nat Rev Clin Oncol 2021; 18: 297-312
24 Garcia-Murillas I, Chopra N, Comino-Méndez I. et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 2019; 5: 1473-1478
25 Tie J, Wang Y, Tomasetti C. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016; 8: 346ra392
26 Trapp E, Janni W, Schindlbeck C. et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst 2019; 111: 380-387
27 Connors D, Allen J, Alvarez JD. et al. International liquid biopsy standardization alliance white paper. Crit Rev Oncol Hematol 2020; 156: 103112